Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2023 Earnings Call Transcript November 2, 2023 Vir Biotechnology, Inc. misses on earnings expectations. Reported EPS is $-1.22 EPS, expectations were $-1.21. Operator: Hello, and welcome to Vir Biotechnology’s Third Quarter 2023 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. At this time, […]
Operator: Hello, and welcome to Vir Biotechnology s Third Quarter 2023 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.
– Company to present new data at AASLD from Phase 2 chronic hepatitis B and chronic hepatitis delta clinical trials –– Company expanding strategic focus to autoimmune diseases and immuno-oncology –– Jennifer Towne, Ph.D., appointed as Executive Vice President and Chief Scientific Officer, effective November 6, 2023.
Longtime BioMarin CEO hands off baton—Chutes & Ladders fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
02.11.2023 - Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2023. “We continue to execute on our multiple clinical stage programs and look forward to sharing Phase .